Compare · RMD vs TELA
RMD vs TELA
Side-by-side comparison of ResMed Inc. (RMD) and TELA Bio Inc. (TELA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and TELA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.02B, about 736.3x TELA ($38.1M).
- Over the past year, RMD is down 21.6% and TELA is down 50.5% - RMD leads by 28.9 points.
- RMD has been more active in the news (7 items in the past 4 weeks vs 1 for TELA).
- RMD has more recent analyst coverage (25 ratings vs 2 for TELA).
- Company
- ResMed Inc.
- TELA Bio Inc.
- Price
- $196.95+1.94%
- $0.94+8.32%
- Market cap
- $28.02B
- $38.1M
- 1M return
- -4.76%
- -14.45%
- 1Y return
- -21.58%
- -50.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 2
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
TELA Bio Inc.
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest RMD
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
Latest TELA
- After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
- Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.
- SEC Form 10-Q filed by TELA Bio Inc.
- TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TELA Bio Reports First Quarter 2026 Financial Results
- TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form DEFA14A filed by TELA Bio Inc.
- SEC Form DEF 14A filed by TELA Bio Inc.
- TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update
- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues